![]() |
市場調查報告書
商品編碼
1499393
基於電動車的液態切片市場:按類型、應用和最終用戶分類 - 2024-2030 年全球預測EV-Based Liquid Biopsy Market by Type (Assay Kits, Instruments, Services), Application (Early Cancer Screening, Recurrence Monitoring, Therapy Selection), End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年基於EV的液態切片市場規模為4.0966億美元,預計2024年將達到4.7312億美元,2030年將達到11.508億美元,複合年成長率為15.89%。
基於 EV 的液態切片包括從體液中提取和分析細胞外囊泡 (EV),代表了非侵入性癌症診斷和監測的開拓前緣。 EV是細胞釋放的脂質結合顆粒,含有豐富的分子訊息,如DNA、RNA和蛋白質,反映了其來源細胞的健康狀況。推動基於 EV 的液態切片的關鍵因素包括其非侵入性、早期癌症檢測的潛力、監測疾病進展和治療反應的能力以及提供腫瘤異質性洞察的能力。然而,這項新興技術面臨挑戰,例如需要標準化的 EV 分離和分析方法、檢測低豐度 EV 的靈敏度以及解釋所獲得的資料的複雜性。解決這些限制需要進行嚴格的研究來建立統一的通訊協定,進步分析技術以提高敏感性和特異性,以及用於資料解釋的複雜的生物資訊工具。研究表明,用於即時監測的照護現場設備的開發、與人工智慧的整合進行預測分析以及擴展到癌症以外的其他疾病正在推動基於 EV 的液態切片在個性化醫療和診斷領域的使用。 。
主要市場統計 | |
---|---|
基準年[2023] | 40966萬美元 |
預測年份 [2024] | 473.12 百萬美元 |
預測年份 [2030] | 11.508 億美元 |
複合年成長率(%) | 15.89% |
區域洞察
美國,特別是美國,由於對醫療保健研發的大量投資以及 FDA主導的強大法規結構,先進診斷解決方案(包括基於 EV 的液態切片)的採用率很高。這種環境培育了競爭格局,許多生技公司和新興企業在電動車研究和診斷方面處於領先地位。在醫療成本上升、患者意識提高和癌症盛行率上升的推動下,以中國和日本等國家主導的亞太地區基於 EV 的液態切片行業正在經歷顯著成長。該地區在政府優惠政策的支持下,專注於基於電動車的創新診斷設備的使用、生產和開發。然而,由於各國地理和經濟差異很大,該地區的市場有些分散。歐洲、中東和非洲地區擁有成熟市場和新興市場的均衡組合,其中西歐在採用基於 EV 的液態切片技術方面處於領先地位,並得到強大的醫療保健系統和對非侵入性診斷的高度認知的支持。隨著公共和私人投資的湧入,加強醫療基礎設施和服務,中東和非洲市場逐漸恢復步伐。
FPNV定位矩陣
FPNV 定位矩陣對於評估基於 EV 的液態切片市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對基於電動車的液態切片市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對基於 EV 的液態切片市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[183 Pages Report] The EV-Based Liquid Biopsy Market size was estimated at USD 409.66 million in 2023 and expected to reach USD 473.12 million in 2024, at a CAGR 15.89% to reach USD 1,150.80 million by 2030.
EV-based liquid biopsy, encompassing the extraction and analysis of extracellular vesicles (EVs) from bodily fluids, represents a pioneering frontier in non-invasive cancer diagnostics and monitoring. EVs, which are lipid-bound particles released from cells, carry a wealth of molecular information, such as DNA, RNA, and proteins, reflective of the health status of their cells of origin. The major factors propelling the use of EV-based liquid biopsies include their non-invasive nature, the potential for early cancer detection, the capability to monitor disease progression and treatment response, and the ability to provide insights into tumor heterogeneity. Nevertheless, this nascent technology faces challenges such as the need for standardized methods for EV isolation and analysis, sensitivity in detecting low-abundance EVs, and the interpretive complexity of the data obtained. Addressing these restraints requires rigorous research to establish uniform protocols, advances in analytical technologies to enhance sensitivity and specificity, and sophisticated bioinformatics tools for data interpretation. The development of point-of-care devices for real-time monitoring, integration with artificial intelligence for predictive analytics, and expansion into other diseases beyond cancer illustrate EV-based liquid biopsy's profound impact on personalized medicine and diagnostic landscapes.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 409.66 million |
Estimated Year [2024] | USD 473.12 million |
Forecast Year [2030] | USD 1,150.80 million |
CAGR (%) | 15.89% |
Regional Insights
In the Americas, particularly the United States, there's a high adoption rate of advanced diagnostic solutions, including EV-based liquid biopsies, driven by substantial investments in healthcare R&D and a robust regulatory framework spearheaded by the FDA. This environment fosters a competitive market landscape, with numerous biotech firms and startups pioneering in EV research and diagnostics. The APAC region, led by countries such as China and Japan, is witnessing major growth in the EV-based liquid biopsy sector, attributed to increasing healthcare expenditure, rising patient awareness, and escalating prevalence of cancer. The region's focus is on the use, production, and development of innovative EV-based diagnostics supported by favorable government policies. However, the market here is somewhat fragmented owing to the vast geographical and economic diversities between countries. The EMEA region demonstrates a balanced mix of mature and emerging markets, with Western Europe at the forefront of adopting EV-based liquid biopsy techniques, backed by strong healthcare systems and high awareness about non-invasive diagnostic methods. The Middle Eastern and African markets are gradually picking up pace, with investments flowing in from public and private sectors to enhance healthcare infrastructure and services.
Market Insights
The market dynamics represent an ever-changing landscape of the EV-Based Liquid Biopsy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the EV-Based Liquid Biopsy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the EV-Based Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
Quest Diagnostics announces the successful completion of its acquisition of Haystack Oncology. This strategic move enriches Quest's portfolio with Haystack Oncology's minimal-residual disease (MRD) testing technology. Leveraging circulating tumor DNA (ctDNA), this advanced MRD testing technology significantly enhances the early detection capabilities for residual or recurring cancers, offering a transformative approach to guiding therapy choices. Quest Diagnostics plans to integrate this cutting-edge technology into developing novel blood-based laboratory services tailored for solid tumor cancers, marking a significant advancement in cancer diagnosis and treatment. [Published On: 2023-06-21]
Agena Bioscience and nRichDX Announce a Commercial Partnership to Create Solutions for the Extraction and Detection of Liquid Biopsy Analytes
Agena Bioscience has solidified its partnership with nRichDX, transitioning from a technical collaboration to a commercial alliance to promote its products within the research community. This partnership heralds significant advancements by coupling Agena's MassARRAY technology with nRichDX's Revolution Sample Prep System, a combination poised to redefine the landscape of liquid biopsy applications. The Revolution Sample Prep System stands out by consistently achieving higher yield extraction of these elusive variant transcripts from bodily fluids, elevating the MassARRAY platform's sensitivity threshold for detecting rare genetic markers in cancer. [Published On: 2023-04-14]
Mercy BioAnalytics Raises USD 41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection
Mercy BioAnalytics, Inc., an innovator in cancer detection through extracellular vesicle-based liquid biopsies, announced the successful closure of a notable USD 41 million in Series A funding. This achievement was led by Novalis LifeSciences and received robust support from a prestigious assembly of investors, including Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, and Broadway Angels. The investment aims to further the development of Mercy BioAnalytics' Mercy Halo platform, which stands out for its exceptional clinical sensitivity and specificity. [Published On: 2023-04-03]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the EV-Based Liquid Biopsy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the EV-Based Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Agena Bioscience, Agilent Technologies, Inc., ALS Automated Lab Solutions GmbH, ANGLE PLC, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, BioFluidica, Biological Dynamics, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Co. KG, Clinomics Europe Ltd., Corning Incorporated, ExosomeDx, Horiba Ltd., Illumina, Inc., Lonza Group Ltd., Malvern Panalytical Ltd., Mercy BioAnalytics, Inc., MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH, Mursla Bio, Nanostics Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, System Biosciences, LLC, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage